PF-04457845

From the notes: PF-04457845 is hands down the cleanest FAAH inhibitor tool out there; it essentially turns up your own anandamide instead of slamming CB1 like THC does, so you get the endocannabinoid tone without the stoned feeling, the munchies, or the memory fog. The selling point is the selectivity; activity-based profiling basically found it hitting FAAH and nothing else, and a single dose keeps the enzyme shut down for about a day.

The human story is genuinely interesting; it flopped in the osteoarthritis knee-pain trial (no better than placebo, which was an honest surprise given how well it worked in rodents), but it later showed real promise cutting cannabis withdrawal symptoms and, in a separate study, boosting fear-extinction recall and blunting stress reactivity; that PTSD angle is pretty much the most exciting direction. Worth being clear-eyed: this is an investigational compound, never approved, and the whole FAAH class carries the shadow of the unrelated BIA 10-2474 tragedy, though PF-04457845 itself has a clean tolerability record across its own trials. It is best regarded as a fascinating research-grade endocannabinoid lever, not a finished product.

PF-04457845 is an investigational compound that has never received regulatory approval. Across its own clinical trials it was well tolerated, with adverse-event rates comparable to placebo and no cannabinoid-type intoxication, even at >96% FAAH inhibition. It was not effective for osteoarthritis knee pain, being no better than placebo. Long-term human safety data are limited to relatively short studies. The broader FAAH-inhibitor drug class is shadowed by the 2016 fatal Rennes trial of the unrelated, less-selective molecule BIA 10-2474; PF-04457845 is a chemically distinct, highly selective compound and was not implicated, but the class history warrants caution. It is a research-grade substance, not a consumer product.